Avidity Biosciences develops targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates platform. The company is focused on addressing unmet patient needs across various therapeutic areas.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

COM:AVIDITYBIOSCIENCES

Avidity Biosciences

Last Close

43.65

21/11 21:00

Market Cap

4.07B

Beta: -

Volume Today

750.46K

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics